CLEC1B and glycogen storage disease VI: GPVI inhibitors have emerged as promising targets to reduce thrombus formation on atherosclerotic plaques and possibly in other atherothrombotic diseases.111 CLEC‐2 is a potential target in the inflamed venous system including DVT and Salmonella‐mediated thrombosis in the liver.